stock commentary: New York

01-06-1992 Comments (0)

3MAbacavirAbarelixAbbott LaboratoriesAbciximabAbilifyActiqActonelActosAdalat CCadalimumabAdefovir DipivoxilAdrenalinAgalsidase BetaAlconAldesleukinAldurazymeAlefaceptAlemtuzumabAlendronate SodiumAlimtaAllegraAllegra-DAllerganAlphaAlphanateAlpharmaAlprostadilAltaceALZA CorpAmeviveAmgenAmino AcidsAmlodipine BesylateAmylinAnakinraAntihemophilic FactorApotexApriAranespAripiprazoleAsmanex TwisthalerAspirinAstraZenecaAtivanAtomoxetine HClatorvastatinAtorvastatin CalciumAvageAvandiaAvaproAvastinAventis PharmaAvinzaAvonexBarr LaboratoriesBASFBasiliximabBaxterBaxter Biopharma SolutionsBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter Healthcare Corporation's BioPharma SolBaxter InternationalBaycolBayerBayerBetaseronbevacizumabbexaroteneBextraBexxarBiaxinBiaxin XLBioclateBiogen IdecbortezomibbosentanBotoxBotulinum Toxin Type ABristol-Myers SquibbBromocriptine MesylateBusparBuspironeByettaCaduetCampathCancidasCaspofungin AcetateCelebrexcelecoxibCelexaCephalonCerivastatinCetirizinecetuximabCialisCiproCiprofloxacinCisapridecitalopramClarinexClarithromycinClaritinClopidogrelCoagulation Factor VIIaConcertaConjugated EstrogensCopaxoneCopegusCozaarCrestorCrixivanCyclosporineCymbaltadaclizumabDarbepoetin AlfaDarifenacin Extended-Release TabletsDenileukin DiftitoxDesloratadineDesogenDesogestrel and Ethinyl Estradiol TabletsDexfenfluramineDitropanDitropan XLdocetaxelDofetilideDrotrecogin alfaDuloxetine HclDuragesicEfalizumabEfavirenzEffexorEffexor XREldeprylEletriptan hydrobromideEloconEmtricitabineEmtrivaEnablexEnalaprilEnbrelEpinephrineEpoetin AlfaEpogenEptifibatideErbituxerlotinibEscitalopram OxalateEsomeprazole MagnesiumEstrogensetanerceptEtodolacEvistaExenatide InjectionezetimibeEzetimibe and SimvastatinFabrazymeFamotidineFenfluramine - Removed from US MarketFentanyl CitrateFentanyl TransdermalFexofenadine HclFexofenadine HCl and Pseudoephedrine HClFilgrastimfinasterideFluMistFlunisolideFluoxetine HclForest LaboratoriesFortametFosamaxFosinopril SodiumgabapentinGabitrilgemcitabine HclGemtuzumab Ozogamicin for InjectionGemzarGenentechGenzymeGeodonGetfitinibGilead SciencesGiliad SciencesGlatiramer AcetateGlaxoSmithKlineGlipizideGlipizide Extended ReleaseGlucophageGlucophage XRGlucotrolGlucotrol XLGlumetzaGSKHalcionHelixate FSHepseraHerceptinHumiraHumulin 70-30Humulin NHumulin RIbritumomab TiuxetanibuprofenIndinavir SulfateinfliximabInfluenza Virus VaccineInjectionInsulinIntegrilinInterferon alfa-2bInterferon beta-1aInterferon beta-1bIntron AirbesartanIressaIvaxIvax PharmaceuticalsJohnson & JohnsonK-LORKadianKineretKing PharmaceuticalsKlor-ConKoateKogenate FSLaronidaseLeukineLevitraLevothyroxine SodiumLevoxylLexaproLillyLipitorLisinoprilLodineLonzaLopressorLoratadineLorazepamLosartan PotassiumLovastatinLucentisMemantine HCLMenestMerck KGaAMerz +MetaxaloneMetformin HclMethylphenidate Extended-Release TabletsMetoprolol TartrateMevacorMitoxantrone for Injection ConcentrateModafinilMometasone FuroateMonoclate-PMonoprilMonsantoMontelukast SodiumMorphine SulfateMorphine Sulfate Extended-ReleaseMotrinMylan LaboratoriesMylotargnaltrexoneNamendaNasalideNasonexNatalizumabNatrecorNebcinnelfinavirNeoralNesiritideNeulastaNeupogenNeurontinNexiumniacinNiaspanNifedipineNitro-DurNitroglycerinNitrostatNolvadexNorplantNorvascNorvirNovantroneNovartisNystatinOlanzapineOmalizumabOmeprazoleOntakOralOral SolutionOrganonOseltamivir PhosphateOxybutynin Chloride Extended Release TabletsOxybutynin Tablets and SyrupPaclitaxelPantoprazoleParlodelparoxetinePaxilPeg-IntronpegfilgrastimPeginterferon alfa-2bPemetrexedPepcidPerkinElmerPfizerPharmaciaPharmacyclicsPhysostigmine SalicylatePioglitazonePlavixPlenaxisPneumococcal 7-valent ConjugatePondiminPotassium ChloridepramlintidePravacholPravastatin SodiumPremarinPrevnarPrilosecPrinivilProcardiaProcritProcter & GambleProlastinProleukinPropeciaPropulsidProscarProstin VR PediatricProtonixProvigilProzacPyrazolopyrimidineQuadrametRaloxifeneRamipril TabletsRanibizumab InjectionRapamuneRaptivaRebetolRebetol and Intron A Combination TherapyRebetronRebifRecombinantRecombinant for InjectionRecombinateReduxRefactoRelenzaRelpaxRemicadeRenagelReoProRestasisRetavaseReteplaseRevatioReviaRezulinRibavirinRiometRisedronate SodiumRisperdalRisperdal ConstaRisperidoneRitonavir CapsulesRituxanrituximabRocheRofecoxibrosiglitazonerosuvastatinSamarium SM 153 LexidronamSandimmuneSandozSankyoSanofi-AventisSargramostimSchering AgSchering PloughSchering-PloughSelegiline HclSertraline HclSevelamer HclShionogiShiresildenafilSimulectSimvastatinSingulairsirolimusSkelaxinSlow-KSonataSpirivaStavudineStratteraStriantSustivaSymlinSynthroidTadalafilTamiflutamoxifenTarcevaTargretinTaxolTaxotereTazaroteneTazarotene GelTazoracTenecteplaseTenofovir Disoproxil FumarateTestodermTestosteroneTetanusTetanus ToxoidThyrogenThyrotropin Alfa for InjectionTiagabine HydrochlorideTikosyntiotropiumTNKaseTobiTobramycinTositumomab and Iodine 1131 TositumomabTracleerTransderm NitrotransdermaltrastuzumabTriazolamTroglitazoneTysabriUCBUnithroidValdecoxibValeant PharmaceuticalsVardenafil HClVasotecVelcadevenlafaxineVenlafaxine Hydrochloride Extended-ReleaseVfendViagraVioxxViraceptVirazoleVireadVoriconazoleVytorinWatson PharmaceuticalsWyethXigrisXolairXynthaZanamivirZenapaxZeritZestrilZetiaZevalinZiagenZiprasidoneZocorZoloftZyprexaZyrtec

NEW YORK: started the reporting week on a high note on expectations of a further interest rate cut, but…

In order to access this content you need to be logged into the site and have an active subscription or trial subscription.  Please login, take a free trial or subscribe in order to continue reading.

A trial subscription will give you access to the latest news on The Pharma Letter for 7 days, in order to evaluate the paid service.   

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days

alt

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £70 per month or £720 per year

alt

  • No-limits access to our the site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. Its part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top